Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00157248 · ClinicalTrials.gov registry record · Phase 2
Long-term, Open-label Follow-up Treatment of Patients With A-fib Who Have Been Previously Treated With BIBR 1048
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Terminated
- Registry status
- Phase 2
- Development phase
- 361
- Enrollment target
NCT00157248 is a Phase 2 study that was terminated before completion, run by Boehringer Ingelheim. The registered enrollment target is 361 participants.
The verdict
NCT00157248, a Phase 2 study, was terminated before completion, sponsored by Boehringer Ingelheim.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 361 participants
- Enrollment target
Study Summary
To determine the long term safety and efficacy of BIBR 1048 in patients with chronic atrial fibrilla tion, with or without concomitant chronic treatment with acetylsalicylic acid (ASA).
Interventions
- DRUG dabigatran etexilate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 361 participants |
| Start Date | 2003-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00157248
The ClinicalTrials.gov registry entry for NCT00157248 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 361 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which dabigatran etexilate is the first listed.
NCT00157248 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00157248 about?
NCT00157248 is a clinical study titled "Long-term, Open-label Follow-up Treatment of Patients With A-fib Who Have Been Previously Treated With BIBR 1048". To determine the long term safety and efficacy of BIBR 1048 in patients with chronic atrial fibrilla tion, with or without concomitant chronic treatment with acetylsalicylic acid (ASA).
What is the current status of trial NCT00157248?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 361 participants. The study started on 2003-12.
What interventions are being tested in trial NCT00157248?
The interventions under investigation include: dabigatran etexilate (DRUG).
Who is sponsoring clinical trial NCT00157248?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.